Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

No CDKN2 mutations in neuroblastomas

C P Beltinger1, P S White, E P Sulman

  • 1Division of Oncology, Children's Hospital of Philadelphia, Pennsylvania 19104-9786, USA.

Cancer Research
|May 15, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glioblastoma stem cells exploit the αvβ8 integrin-TGFβ1 signaling axis to drive tumor initiation and progression.

Oncogene·2017
Same author

Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma.

Oncogene·2016
Same author

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.

British journal of cancer·2015
Same author

Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.

Clinical pharmacology and therapeutics·2014
Same author

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.

Bone marrow transplantation·2013
Same author

Controversies in the specialist management of adult epistaxis: an evidence-based review.

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·2012

The CDKN2 gene, often mutated in cancers like melanoma, was analyzed in neuroblastoma tumors. No mutations or deletions were found, indicating CDKN2 gene disruption is not essential for neuroblastoma development.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • The CDKN2 gene is frequently altered in various cancers, including melanoma.
  • Neuroblastoma and melanoma share a neuroectodermal origin and chromosome 1p deletions.
  • Investigating CDKN2 in neuroblastoma is relevant due to these shared characteristics.

Purpose of the Study:

  • To investigate the role of the CDKN2 gene in the pathogenesis of human neuroblastomas.
  • To determine if mutations or deletions in CDKN2 are present in primary neuroblastomas and derived cell lines.

Main Methods:

  • Analysis of 18 primary neuroblastomas and 9 neuroblastoma cell lines.
  • PCR-single-strand conformation polymorphism (PCR-SSCP) used to screen CDKN2 exons 1 and 2 for mutations.
  • Assessment for homozygous deletions of CDKN2 and loss of heterozygosity (LOH) at the IFNA locus.

Related Experiment Videos

Main Results:

  • No mutations were detected in exons 1 and 2 of the CDKN2 gene across all analyzed samples.
  • No homozygous deletions of the CDKN2 gene were found.
  • Loss of heterozygosity was not observed at the closely linked IFNA locus.

Conclusions:

  • The CDKN2 gene is not a frequent target of mutation or deletion in human neuroblastomas.
  • Disruption of the CDKN2 gene is not a necessary event for the malignant transformation of neuroblastoma.